Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges

Dr Reddys Laboratories, a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline of 3.03% on August 1, 2025. This downturn marks the third consecutive day of losses for the stock, which has seen a total drop of 5.35% over this period. The stock reached an intraday low of Rs 1230.8, reflecting a decrease of 3.15% during the trading session.
In comparison to the broader market, Dr Reddys Laboratories underperformed, with a daily performance of -3.36% against the Sensex's decline of 0.29%. Over the past week, the stock has fallen by 3.84%, while the Sensex has decreased by 0.62%. On a monthly basis, Dr Reddys Laboratories has seen a decline of 3.83%, slightly worse than the Sensex's drop of 3.28%.

Despite these recent challenges, the stock remains above its 100-day moving average, although it is currently below its 5-day, 20-day, 50-day, and 200-day moving averages. The Pharmaceuticals & Drugs sector overall has also faced a decline of 2.21%, indicating a challenging environment for the industry.